Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin-loaded versus epirubicin-loaded TACE for BCLC-B hepatocellular carcinoma
ChiCTR2000034758Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of idarubicin and epirubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Progression-free survival. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
idarubicinepirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000034758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034758.